Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. - Test2 - elhamkhani - TriplyDB

Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.

Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.

http://www.wikidata.org/entity/Q34596182

about

Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis Genetics and biology of pancreatic ductal adenocarcinoma Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up GEMMs as preclinical models for testing pancreatic cancer therapies Critical role of NF-κB in pancreatic cancer Role of oxidative stress and the microenvironment in breast cancer development and progression Oncolytic viral therapy for pancreatic cancer: current research and future directions Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing.Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers.Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer EGF receptor is required for KRAS-induced pancreatic tumorigenesis EMT and dissemination precede pancreatic tumor formation Pancreatic cancers require autophagy for tumor growth Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy.Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer Molecular imaging agents: impact on diagnosis and therapeutics in oncology Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.Pancreatic cancer.Transplanting normal vascular proangiogenic cells to tumor-bearing mice triggers vascular remodeling and reduces hypoxia in tumors Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells.Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.A mouse to human search for plasma proteome changes associated with pancreatic tumor development.Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas.Prediction of epigenetically regulated genes in breast cancer cell lines Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression.RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer.Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma.Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity Racial disparity in metabolic regulation of cancer.Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis.

P2860

Q21144653-5737BEE8-4D39-4C7B-BC3E-020ECD3EEE7B Q21245763-E4518041-6361-4310-8062-53F36E609451 Q24603754-1776A113-8E0A-4F2A-9B38-7EEAD3E5541B Q24626854-5D96B5E1-DA5D-40BC-B33F-CBAED76DBCEC Q26765438-8727F795-00E0-49CA-9EE9-61A17D6F9BDB Q26766039-68FD44B3-6746-4C2A-AB5E-179CBCC30A95 Q26780372-3D38042A-8E00-46EF-8387-1551D9F25AC4 Q26781848-F046F824-F7AB-40D3-965C-0F2890B99A91 Q26864198-FFB60A40-6E23-4BBF-ADE6-DA2E017079E7 Q27003859-48C830BB-4612-461C-9FCA-9702687EEDC2 Q27011439-0C1DBB2B-AAE6-4B23-8AE9-80243303963F Q27322787-A26E2511-3760-48B3-A6CD-39FB9B03D48A Q27329427-690C1288-28AE-4948-B033-79EDC13A9C17 Q27348974-3299E031-39FB-444F-8B67-C383558E6E2A Q27853310-0ECDC103-65A6-450A-9D64-6661930AF140 Q28289209-1266DCE1-2425-4F0A-B6FB-803D0697491B Q28478758-A6725DC1-6B35-498E-9F4A-AF558F18E295 Q28584901-61EDA809-809F-4FD3-9A08-003B6E0590FA Q29615854-BA6E6701-7FC0-4B0D-8B80-6DCE6681A764 Q29620331-F032B312-1F43-4B65-8979-D6720FF0F6E3 Q30388746-1DF92CE5-CC2A-4F1F-8FD4-3E22B990910B Q30410012-57678AF7-A01A-42B5-8B17-777E000B309A Q30433423-C94274D5-1044-4E47-BD55-2AE260E184B3 Q30472055-0E8F0AF1-AF19-45EC-8FCF-B69F2D40493F Q30490247-0186B6D2-7C02-4DFE-96DD-9AAA1C6C0DF7 Q30499092-FDB1580F-BF52-430B-94C6-1B206BF99767 Q30536268-8F31B0B8-C206-4F02-808E-70BF8947E7FD Q30803684-B0ECA652-8791-4ECA-8481-B111E44C7140 Q33343004-5BA73BDF-FD2A-4CFA-A40C-F6F58C4F7141 Q33486497-E4DAFB77-9427-4358-A2DF-561A752F277E Q33595315-462281E9-BED1-40B5-A421-909C479CB4C8 Q33635144-4DAA3306-7E13-46AB-96C4-4554EBFFA7F6 Q33718581-386DF993-6E19-444D-B5EB-2983BF48A82B Q33726461-16583688-E2D8-4191-93EC-BAEBB0A86562 Q33779491-09A00A87-04EE-41CE-81FF-8141B6CD8E50 Q33858490-C0102022-3A7E-45F7-B27C-382ADD195FAC Q33882228-A75356BA-2D96-4925-9931-37CD82A3D59F Q33883227-2BF8E234-FF45-4520-B319-6F9764973B34 Q33906704-3900CDCF-33E5-4567-88EA-57B48D373EE6 Q33910221-2676AA49-2FE9-4B40-924D-5E417C426134

P2860

Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.

http://www.wikidata.org/entity/Q34596182

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Both p16

@nl

Both p16(Ink4a) and the p19(Ar ...... c adenocarcinoma in the mouse.

@ast

Both p16(Ink4a) and the p19(Ar ...... c adenocarcinoma in the mouse.

@en

type

label

Both p16

@nl

Both p16(Ink4a) and the p19(Ar ...... c adenocarcinoma in the mouse.

@ast

Both p16(Ink4a) and the p19(Ar ...... c adenocarcinoma in the mouse.

@en

prefLabel

Both p16

@nl

Both p16(Ink4a) and the p19(Ar ...... c adenocarcinoma in the mouse.

@ast

Both p16(Ink4a) and the p19(Ar ...... c adenocarcinoma in the mouse.

@en

P1433

Q34596182-73FB554C-911B-4A10-8948-A38F629A055D

P1476

Q34596182-8ED3BE74-30E3-473C-84B5-D3923F130306

P2093

Q34596182-50BEC4DC-F4D3-43DA-8BE7-16B9222CFAFB

Q34596182-6B3C23A8-FE00-41D7-84B9-D95E1C4E168C

Q34596182-7563AE01-FC52-4451-B84E-977786A86D9F

Q34596182-7B08867A-E79A-4CC8-8277-E3E3D66A97D5

Q34596182-842736EB-A4B0-4482-ACE6-D82B62FFD5B0

Q34596182-A191824C-0BAC-4374-BDDC-5440951C8251

Q34596182-C6E4904B-D16F-43A6-809E-831C7987CF6B

Q34596182-DE6945B9-4AD8-4317-B9B6-FAB2A40B7037

Q34596182-E6A4A396-E274-4358-B9E5-BBFD62F3A600

Q34596182-EE12DC5E-25AD-4B16-AB51-CA99C8C61C89

P2860

Q34596182-04F81702-47B1-4704-AAFA-4167A9D2FEDA

Q34596182-0E086004-4320-4804-B17E-2899EEE6F99F

Q34596182-1A5CC274-6853-43D8-8849-389D529D56BE

Q34596182-2A39CF66-E685-4D76-8779-D3A1C7E3E787

Q34596182-305DF114-8951-47BA-9D71-A56C3F78B43E

Q34596182-349210C6-EFA1-436E-806A-9C163F246477

Q34596182-39878AA8-0CC5-451C-806A-18982A89F0AC

Q34596182-3A11551C-181E-4A8D-8674-484FC70866AC

Q34596182-3D54FBD4-73FA-4EA9-AEBD-463479CE4690

Q34596182-4C8240C0-E76A-4355-BA7F-D18FE9785FD3

P304

Q34596182-0992B6F6-EF51-4734-8046-E1954B6496EE

P31

Q34596182-28D30C53-6961-4E4E-A130-924B558905EE

P356

Q34596182-E57B5A55-97EE-436E-B585-7976D6FA7D66

P407

Q34596182-A247B032-4965-4F41-A736-FF261DC3A2E3

P433

Q34596182-5F36448E-930A-4341-9E6A-8AA39035F856

P478

Q34596182-8AA8A45D-8E01-462D-ABBD-F5E7B339718F

P50

Q34596182-6AABD53B-6741-410A-B5E9-03BB39D210A2

Q34596182-77C66BBE-112F-43AA-B11C-B01D29A2AC98

Q34596182-B3AAC0EA-B5A8-4C04-AB65-7573392C4AC7

Q34596182-CE519A63-5B80-44DD-A6E8-C90DC4ACA5F1

P577

Q34596182-BD06069F-D545-4288-B856-1E66538BA513

P5875

Q34596182-8A64D679-633E-4960-8980-C2ABCA58CD87

P698

Q34596182-C42FD699-4A92-4A85-8783-4B4AFD0E58C6

P921

Q34596182-BB13BD72-4EAA-48D1-93A4-2B80B301D2D3

P932

Q34596182-4B3EE942-A1D9-480D-8726-52A7A8FBD7B7

P356

PNAS.0601273103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Both p16(Ink4a) and the p19(Ar ...... c adenocarcinoma in the mouse.

@en

P2093

Andrew J Aguirre

http://www.w3.org/2001/XMLSchema#string

Aram F Hezel

http://www.w3.org/2001/XMLSchema#string

Bin Feng

http://www.w3.org/2001/XMLSchema#string

Douglas Hanahan

http://www.w3.org/2001/XMLSchema#string

Gerald C Chu

http://www.w3.org/2001/XMLSchema#string

Kuang-Hung Cheng

http://www.w3.org/2001/XMLSchema#string

Lyle V Lopez

http://www.w3.org/2001/XMLSchema#string

Mark S Redston

http://www.w3.org/2001/XMLSchema#string

Nabeel Bardeesy

http://www.w3.org/2001/XMLSchema#string

Ronald A Depinho

http://www.w3.org/2001/XMLSchema#string

P2860

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Cluster analysis and display of genome-wide expression patterns

Global cancer statistics, 2002

Tumor suppression by Ink4a-Arf: progress and puzzles

Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

Live or let die: the cell's response to p53

Cancer statistics, 2005

Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors

P304

5947-5952

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0601273103

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Nabeel Bardeesy

Cameron Brennan

Ralph Weissleder

P577

2006-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7193647

http://www.w3.org/2001/XMLSchema#string

P698

16585505

http://www.w3.org/2001/XMLSchema#string

P921

P932

1458678

http://www.w3.org/2001/XMLSchema#string